KOSDAQBiotech & Pharma420570

J2KBIO

₩8,060▼ 0.86%2026-11-18 close
Market Cap
₩47.1B
Turnover
₩82,187,850
Volume
10K
Shares out.
5.9M
PER
6.5×
PBR
1.2×
EPS
₩1,203
Dividend Yield
3.18%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩250 per share · Prices as of the 2026-11-18 close

01

Report overview

Record Quarterly Sales on K-Beauty Demand, Clinic Losses Still a Hurdle

J2KBIO's cosmetic ingredient orders rose with K-beauty exports, lifting Q2 2026 sales to the largest quarter in its filed record, but losses at its skin clinic and the operating profit decline since 2024 remain unresolved.

  1. 1

    Q2 2026 revenue of KRW 15.6 billion was the largest quarter in the filed record. Q3 2026 revenue of KRW 13.6 billion fell 12.8% from the prior quarter.

  2. 2

    Operating profit peaked at KRW 5.61 billion in 2023, then fell to KRW 3.63 billion in 2024 and KRW 2.92 billion in 2025, when the operating margin was 8.9%.

  3. 3

    Net profit attributable to controlling shareholders swung from a net loss of KRW 1.65 billion in 2024 to KRW 2.67 billion in 2025, and every quarter from Q1 to Q3 2026 was profitable.

  4. 4

    The skin clinic began operating in May 2024 and is still loss-making, and the company has set a target of reaching breakeven in 2027.

  5. 5

    An October 2026 MOU with Cassava Pharma secured domestic supply rights for 11 tapioca-starch-based ingredients, and the timing of supply launch and the scale of any revenue contribution remain items to watch.

02

Business structure

J2KBIO was founded in 2017 and listed on KOSDAQ in 2024. It develops and produces natural and bio-based ingredients for cosmetics. Its own library of roughly 1,000 skin-beneficial microbial strains is registered with the Korean Collection for Type Cultures, which the company says gives it exclusive usage rights.

Production takes place in Osong, Chungbuk, and as of its Q1 2024 disclosure materials the annual capacity was 3,230 tons.

Its main customers are large domestic cosmetics manufacturers such as Kolmar Korea-type ODM and OEM groups, and the direct export share is small, but orders rise when customers' products sell overseas.

A brokerage report from December 2025 showed natural-ingredient sales of KRW 3.4 billion, down 11% year on year, and bio-ingredient sales of KRW 2.1 billion, up 39%, in its product breakdown.

Within bio-ingredients, the company is raising the share of higher-value products such as PDRN and peptides, which it says strengthens profitability relative to commodity ingredients.

Its skin clinic, HLK Clinical Center, began operating in May 2024 and is currently loss-making because of equipment depreciation and staff costs. In September 2026 it launched the J2K METABIOME.ai library platform for discovering new ingredients and plans to introduce AI.

On October 28, 2026 it signed an MOU with Cassava Pharma for a Korean distributorship and US distribution cooperation, securing domestic supply rights for 11 tapioca-starch-based ingredients.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.6B₩1.2B14.6%
2025Q4₩8.6B₩600M7.5%
2026Q1₩11.1B₩1.9B17.2%
2026Q2₩15.6B₩2.7B17.3%
2026Q3₩13.6B₩2.6B19.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16B₩2.3B₩2.1B14.5%19.2%61.7%
2023₩28.5B₩5.6B₩4.8B19.7%27.2%23.6%
2024₩33.1B₩3.6B-₩1.7B10.9%−5.3%14.7%
2025₩33B₩2.9B₩2.7B8.9%7.9%12.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-11

04

Earnings analysis

Annual revenue rose from KRW 16 billion in 2022 to KRW 28.5 billion in 2023, a 77.6% increase, and reached KRW 33.1 billion in 2024, up 16.4%, making 2024 the largest year of 2022–2025. Revenue was KRW 33 billion in 2025, down 0.5%.

Operating profit peaked at KRW 5.61 billion in 2023, up 141.3%, then fell 35.3% to KRW 3.63 billion in 2024 and 19.5% to KRW 2.92 billion in 2025, a two-year decline. The operating margin moved from 14.5% in 2022 and 19.7% in 2023 to 10.9% in 2024 and 8.9% in 2025, so revenue held up while margins compressed.

The company attributed the 2024 profit drop to one-off costs, including clinic investment and special bonuses tied to the listing.

In 2024 higher non-operating expenses from the SPAC merger pushed the company to a net loss attributable to controlling shareholders of KRW 1.65 billion, and in 2025 those expenses normalized, returning it to a profit of KRW 2.67 billion.

Operating cash flow was KRW 1.45 billion in 2022, KRW 3.29 billion in 2023, and KRW 6.93 billion in 2024, before falling to KRW 2.03 billion in 2025. The debt ratio fell from 61.7% in 2022 to 12.7% in 2025, with total equity of KRW 33.8 billion and total liabilities of KRW 4.29 billion at end-2025.

Quarterly revenue climbed from KRW 8.56 billion in Q3 2025 to KRW 15.6 billion in Q2 2026, the highest in the filed record, before falling 12.8% to KRW 13.6 billion in Q3 2026.

Quarterly operating profit bottomed at KRW 643 million in Q4 2025 and recovered to KRW 1.91 billion in Q1 2026, KRW 2.69 billion in Q2, and KRW 2.61 billion in Q3. Net profit attributable to controlling shareholders over the last four quarters totaled KRW 7.04 billion.

One media outlet described Q2 2026 revenue as the largest quarterly sales on record, and the company attributed growth to higher supply to large existing customers and new brand and mid-sized customers.

05

Industry analysis

J2KBIO's sales track how much cosmetics makers produce, so whether Korean cosmetics exports convert into ingredient orders is the central variable. Cosmetics exports in August 2026 rose 52.1% year on year to USD 1.31 billion. Exports for September 1–10 rose 46.1% over the same period a year earlier.

The export market is also widening from North America toward Europe and Latin America. In its Q2 2026 disclosure the company pointed to overseas expansion by existing ODM customers and new brand customers as the basis for second-half growth.

Before its listing, in a 2024 press briefing, the company said the shift from synthetic to fermented, bio-based materials was continuing. Its Q1 2024 disclosure cited more than 300 domestic and overseas customers.

A brokerage view also holds that its fermented-microbe materials have drawn positive responses from ODM and indie-brand clients. Supply of pharmaceutical and health-food excipients would add demand sources beyond the cosmetics export cycle.

06

Outlook

In its Q2 2026 disclosure the company said it expects growth to continue in the second half, based on overseas expansion by existing ODM customers and the addition of new brand customers.

A company official said growth was broad-based across major customers and existing and new accounts, and expressed expectations for a solid second half.

The clinic remains loss-making due to equipment depreciation and staff costs, and the company plans to raise utilization by winning clinical-trial orders from external brands and OEM and ODM clients.

It plans to extend overseas sales to North America, Taiwan, and Japan, and has set a target of reaching breakeven in 2027. The CEO described the next three to five years as a period of shifting the portfolio from commodity ingredients to higher-value bio-based materials.

Under the Cassava Pharma MOU, the parties will explore using Cassava's US network and the possible entry of the company's bioactive materials into the US market.

In its corporate value-up plan the company set a target of a price-to-book ratio above 2x by 2028 and proposed a dividend payout ratio of at least 25% as part of its shareholder return measures. Its new ingredient platform also plans to introduce AI to improve data analysis efficiency.

The next checkpoints are whether quarterly revenue after Q4 2026 recovers to the Q2 2026 level, and whether clinic losses narrow in line with the 2027 breakeven target.

07

Valuation

PER
6.5×
PBR
1.2×
ROE
19.6%
EPS
₩1,203
BPS
₩6,605
Dividend per share
₩250

Rather than citing point values, the valuation can be read in relative terms: the price-to-book ratio sits below the more than 2x level the company set as its 2028 target.

Net profit attributable to controlling shareholders over the last four quarters totaled KRW 7.04 billion, following a return to profit from the 2024 net loss. However, operating profit remains below its 2023 peak and quarterly swings are large, so multiples need to be read alongside the earnings trend.

The company has proposed a dividend payout ratio of at least 25% as part of its shareholder return measures, and the dividend yield moves with the share price. A debt ratio of 12.7% indicates a light financial burden.

How far the share price already reflects the earnings recovery is a question best answered by comparing price movements with the quarterly earnings trend.

Because quarterly profits have recovered in 2026, whether this trend holds in the next periodic reports will serve as the reference point for interpreting the multiple.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-11

08

Bull factors

Export-linked order growth

Cosmetics exports rose 52.1% year on year in August 2026, which supports the growth in ingredient orders. As customers' overseas sales expand, orders for ingredients rise alongside them. Q2 2026 revenue was the largest quarter in the filed record.

Quarterly profit recovery

Quarterly operating profit recovered from KRW 643 million in Q4 2025 to KRW 1.91 billion in Q1 2026, KRW 2.69 billion in Q2, and KRW 2.61 billion in Q3. Net profit attributable to controlling shareholders stayed positive from Q1 to Q3 2026.

This runs against the annual trend of margin decline and points in a favorable direction for quarterly earnings.

Higher-value materials and new supply rights

The company says it is raising the share of higher-value bio-ingredients such as PDRN and peptides. Through the Cassava Pharma MOU it secured domestic supply rights for 11 tapioca-starch-based ingredients, and plans to widen its customer base to pharmaceutical and health-food makers.

09

Bear factors

Persistent clinic losses

The skin clinic is currently loss-making because of equipment depreciation and staff costs. In the first half of 2026, expanded clinic investment and overseas sales development costs also weighed on profitability. The 2027 breakeven target the company set has not yet been reached.

Declining operating margin

The operating margin fell from 19.7% in 2023 to 8.9% in 2025. Operating profit declined in both 2024 and 2025. Q3 2026 revenue fell 12.8% from the prior quarter, showing quarterly volatility.

Domestic customer base and earnings volatility

Major customers are concentrated among large domestic cosmetics makers and OEM and ODM firms, so order changes from individual clients feed directly into results.

Net profit attributable to controlling shareholders swung from a 2024 loss to a 2025 profit, and the record shows large swings driven by one-off items such as the SPAC merger.

10

Risk factors

Export-cycle risk

Ingredient demand depends on overseas sales of Korean cosmetics. A slowdown in cosmetics exports could reduce customer orders. Continued export growth is not assured.

Customer concentration and order volatility

Key customers are large domestic cosmetics makers, OEM and ODM firms, and indie brands. Quarterly sales can swing sharply depending on when these customers place orders. The decline in Q3 2026 revenue from the prior quarter illustrates this volatility.

Execution risk on new businesses

The clinic is loss-making, and the Cassava Pharma collaboration is at the MOU stage, with supply launch timing and sales scale not yet set. If new-business investment does not convert to profit by the target dates, the cost burden could persist.

11

What to watch next

  1. Around February 2027

    The full-year 2026 results release will show whether Q4 2026 revenue holds near the Q3 level of KRW 13.6 billion and whether the operating margin exceeds 8.9% in 2025.

  2. Late March 2027

    The 2026 annual report and the regular shareholders' meeting are due. The annual report finalizes full-year results, and whether the at-least-25% payout policy translates into dividend decisions is a point to confirm.

  3. Mid-May 2027

    The Q1 2027 report is the first quarterly checkpoint for whether clinic losses narrow and whether overseas expansion shows up in revenue.

  4. Ongoing disclosures (timing undecided)

    Confirmation of when Cassava Pharma ingredient supply begins in Korea and whether the US distribution cooperation is implemented. Launch timing and revenue scale should be confirmed through disclosures.

12

Overall view

J2KBIO recorded its largest quarter in the filed record in Q2 2026, with orders linked to K-beauty exports, and both quarterly operating profit and net profit attributable to controlling shareholders recovered from Q1 to Q3 2026.

On an annual basis, however, operating profit fell in both 2024 and 2025 after peaking in 2023, and the operating margin dropped to 8.9%, so sales growth has not translated into margin improvement. The skin clinic began operating in May 2024 and is still loss-making, and the company has set a 2027 breakeven target.

The Cassava Pharma MOU and the shift toward higher-value bio-materials broaden the business scope, but supply launch timing and revenue scale remain unconfirmed.

The balance sheet is light, with a debt ratio of 12.7%, and valuation should be read together with whether the quarterly earnings trend continues in upcoming periodic reports. The next checkpoints are the 2026 full-year results, the 2026 annual report, and the Q1 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. paxetv.com
  2. markets.hankyung.com
  3. press.hyundaenews.com
  4. m.news.nate.com
  5. etoday.co.kr
  6. alphasquare.co.kr
  7. pharmnews.com
  8. investkorea.org
  9. kind.krx.co.kr
  10. newswell.co.kr
  11. fnnews.com
  12. alphabiz.co.kr
  13. m.news.nate.com
  14. m.news.nate.com
  15. seoulexchange.kr
  16. pharmnews.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis